

A note on the functions of bcl-2 in human solid tumors in situ

Y. Kuwashima

Department of Laboratory Medicine, Hanyu General Hospital - Hanyu, Saitama (Japan)

Summary

Dual functions of bcl-2 product, (1) inhibition of apoptosis and (2) inhibition of cell growth, were analyzed in human endometrial adenocarcinoma tissue using serial tissue sections and immunohistochemical and histochemical procedures. As conclusion, bcl-2 product was speculated to have at least two functions; (1) suppression of apoptosis of cells in G0 phase, and (2) blocking the entrance of G0 cells into cell division cycle.

Introduction

Bcl-2 has been known to protect cells from apoptosis in normal and malignant tissues [1, 2]. In addition, overexpression of bcl-2 inhibits growth of solid tumor cells in vitro [3]. Thus the function(s) of bcl-2 product seems to be dual when one considers prolongation of life and inhibition of growth of the cells. To demonstrate these two aspects of bcl-2 function(s) in human solid tumor in vivo, we performed serial section analysis of 10 cases of human endometrial adenocarcinomas [4-6]. All the cases were well-differentiated types and had not undergone preoperative chemotherapy.

Materials and Methods

Immunohistochemical or histochemical procedures were applied to formalin-fixed and paraffin-embedded tissue which had been serially cut 1 micrometer in thickness. The section series were stained with hematoxylin eosin, Ki-67 (immunostain) and bcl-2 (immunostain), and DNA-nick ends labeled by NEL, a modified method of TUNEL [7].

At first, bcl-2 staining pattern (normal lymphocytes were used as an internal control because of their constant strong signal) and NEL signal were compared and analyzed [4]. As in Fig. 1, bcl-2 positive carcinoma nests tended to be NEL negative, indicating that bcl-2 blocks in general apoptotic DNA fragmentation in human endometrial adenocarcinoma.

Then, the status of bcl-2 expression and cell proliferation was compared and analyzed [5]. Presence of Ki-67 antigen was used as a hallmark of proliferating cells, and Ki-67 negative cells were judged as those in the G0 phase [8, 9]. As shown in Fig. 2-1, an inverse correlation was found between the degree of bcl-2 expression and cell growth fraction (fraction of proliferating tumor cells of the total tumor cells); the quantitative data have been already described in reference no. 5.

Results

The results indicate that bcl-2 overexpression is found mainly in the G0 cell population. This fact indicates

further that bcl-2 blocked G0 cells from entering the cell cycle, in other words possible "growth inhibition" by bcl-2 product.

From these two results, we suggest that bcl-2 inhibits apoptosis of cells mainly in the G0 phase. In cultured cells, a correlation between an apoptosis – suppressing effect of bcl-2 and cell cycle status has not yet been established [10, 11]. To conform this speculation, the correlation between Ki-67 stain, NEL and bcl-2 immunostain was analyzed [6]. As shown in Fig. 2-2, even when bcl-2 overexpression was absent, apoptotic DNA fragmentation occurred randomly irrespective of phases in the cell cycle (quantitative data were given in reference no. 6). The fact that a random distribution of apoptosis is shown throughout the cell cycle including G0 was already reported in the in vitro system [12]. Thus, apoptosis in G0 cells certainly exists among human endometrial adenocarcinomas, and this supports the above hypothesis that "bcl-2 suppresses apoptosis of cells mainly in G0".

Conclusions

In conclusion, we speculate that bcl-2 product has at least two functions: (1) suppression of apoptosis of cells in the G0 phase, and (2) blocking the entrance of G0 cells into the cell division cycle.

It should be necessary to clarify a correlation of the above-mentioned two functions. This problem could be a key point in understanding the correlation between prolongation of the life and growth potential of cells.

Acknowledgement

This communication was based on the results in our previous three articles (references no. 4-6), and the figures were taken from the articles.

The authors thank Drs. Moriaki Hayashi and Hiromichi Matsudaira for their expert advice.






Figure 1. — Staining results for bcl-2 products (A, ++; C, +; E, -) and NEL (B, D, F). Bcl-2 positive cells are generally NEL negative. Staining intensity for bcl-2 was expressed as negative (-), weakly positive (+) or strongly positive (++), in comparison with that of normal lymphocytes used as a standard. (Taken from Kuwashima et al. 1996, ref. no. 4).



bcl-2

Ki-67

Figure 2.1. — Low magnification view of the carcinoma stained for bcl-2 (A) and Ki-67 (B). Bcl-2 positive nests (right) are almost Ki-67 negative, and bcl-2 negative nests (left) contained a large number of Ki-67 positive nuclei. (Taken from Kuwashima et al. 1997, ref. no. 5).



Ki-67

NEL

bcl-2

Figure 2.2. — Staining results for Ki-67 (A), NEL (B) and the bcl-2 product (C). Arrows indicate "proliferating apoptotic cells" and arrow heads "quiescent apoptotic cells". (Taken from Kuwashima et al. 1997, ref. no. 6).

References

- [1] Ly Q-L., Poulson R., Wong L., Hanby A.: "Bcl-2 expression in adult and embryonic non-hematopoietic tissue". *J. Pathol.*, 1993, 169.
- [2] Korsmeyer S. J.: "Bcl-2: an antidote to programmed cell death". *Cancer Surv.*, 1992, 15, 105.
- [3] Pietenpol J. A., Papadopoulos N., Markowitz S., Willson J. K. V. et al.: "Paradoxical inhibition of solid tumor cell growth by bcl-2". *Cancer Res.*, 1994, 54, 3714.
- [4] Kuwashima Y., Kobayashi Y., Kawarai A., Uehara T. et al.: "Expression of bcl-2 and apoptotic DNA fragmentation in human endometrial adenocarcinoma". *Anticancer Res.*, 1996, 16, 3221.
- [5] Kuwashima Y., Kobayashi Y., Kurosumi M., Tanuma J. et al.: "Inverse correlation between bcl-2 expression and cell growth fraction in human endometrial adenocarcinoma tissue". *Anticancer Res.*, 1997, 17, 3773.
- [6] Kuwashima Y., Kobayashi Y., Kawarai A., Kurosumi M. et al.: "Occurrence of apoptotic DNA fragmentation in quiescent and proliferating cells in human endometrial adenocarcinoma tissues and the influence of apoptosis-suppressing effects of bcl-2 products". *Anticancer Res.*, 1997, 17, 3737.
- [7] Gavrieli Y., Sherman Y., Ben-Sasson S. A.: "Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation". *J. Cell. Biol.*, 119, 493, 1992.
- [8] Gerdes J., Lemke H., Baisch H., Wacker H-H. et al.: "Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67". *J. Immunol.*, 1984, 133, 1710.
- [9] Schluter C., Duchrow M., Wohlenberg C., Becker M. H. G. et al.: "The cell-proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins". *J. Cell. Biol.*, 1993, 123, 513.
- [10] Wanger A. J., Small M. B., Hay N.: "Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2". *Mol. Cell. Biol.*, 1993, 13, 2432.
- [11] Tarui Y., Furukawa Y., Kikuchi J., Saito M.: "Apoptosis during HL-60 cell differentiation is closely related a G0/G1 cell cycle arrest". *J. Cell. Physiol.*, 1995, 164, 74.
- [12] Lindenboim L., Diamond R., Rothenberg E., Stein R.: "Apoptosis induced by serum deprivation of PC12 cells is not preceded by growth arrest and can occur at each phase of the cell cycle". *Cancer Res.*, 1995, 55, 1242.

Address reprint requests to:
Y. KUWASHIMA
Department of Laboratory Medicine
Hanyu General Hospital
551 Kamiwase, Hanyu, Saitama 348-8505 (Japan)